By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login
Logo for company Coloplast A/S

Coloplast A/S (CLPBY)

OTC Market Data in USD, Fundamentals in DKK
$9.64
+$0.08
+0.84%
Last Update: 29 Aug 2025, 19:58
$21.62B
Market Cap
3.72
P/E Ratio (TTM)
1.56%
Forward Dividend Yield
$9.16 - $14.14
52 Week Range

CLPBY Stock Price Chart

Explore Coloplast A/S interactive price chart. Choose custom timeframes to analyze CLPBY price movements and trends.

CLPBY Company Profile

Discover essential business fundamentals and corporate details for Coloplast A/S (CLPBY) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Medical - Instruments & Supplies

IPO Date

13 Jan 2014

Employees

16.74K

CEO

Anders Lonning-Skovgaard

Description

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates in three segments: Chronic Care, Interventional Urology, and Wound & Skin Care. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include bathing and cleansing products, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.

CLPBY Financial Timeline

Browse a chronological timeline of Coloplast A/S corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 4 May 2026

Upcoming earnings on 2 Feb 2026

Upcoming earnings on 4 Nov 2025

Earnings released on 19 Aug 2025

EPS came in at $0.06 falling short of the estimated $0.11 by -45.50%, while revenue for the quarter reached $1.09B , missing expectations by -84.61%.

Earnings released on 6 May 2025

EPS came in at $0.06 falling short of the estimated $0.09 by -34.75%, while revenue for the quarter reached $1.02B , missing expectations by -85.77%.

Dividend declared on 6 May 2025

A dividend of $0.08 per share was announced, adjusted to $0.08. The dividend was paid on 22 May 2025.

Earnings released on 4 Feb 2025

EPS came in at $0.07 falling short of the estimated $0.08 by -12.50%, while revenue for the quarter reached $972.40M , missing expectations by -0.54%.

Dividend declared on 11 Nov 2024

A dividend of $0.24 per share was announced, adjusted to $0.24. The dividend was paid on 20 Dec 2024.

Earnings released on 5 Nov 2024

EPS came in at $0.08 falling short of the estimated $0.09 by -6.61%, while revenue for the quarter reached $1.04B , beating expectations by +2.23%.

Earnings released on 20 Aug 2024

EPS came in at $0.08 falling short of the estimated $0.09 by -8.68%, while revenue for the quarter reached $991.37M , beating expectations by +0.20%.

Dividend declared on 8 May 2024

A dividend of $0.07 per share was announced, adjusted to $0.07. The dividend was paid on 28 May 2024.

Earnings released on 7 May 2024

EPS came in at $0.08 matching the estimated $0.08, while revenue for the quarter reached $945.75M , missing expectations by -2.35%.

Earnings released on 5 Mar 2024

EPS came in at $0.82 surpassing the estimated $0.08 by +907.75%, while revenue for the quarter reached $974.84M , beating expectations by +0.87%.

Dividend declared on 16 Nov 2023

A dividend of $0.23 per share was announced, adjusted to $0.23. The dividend was paid on 22 Dec 2023.

Earnings released on 30 Sept 2023

EPS came in at $0.77 surpassing the estimated $0.09 by +777.77%, while revenue for the quarter reached $878.49M , missing expectations by -3.40%.

Earnings released on 30 Jun 2023

EPS came in at $0.87 surpassing the estimated $0.09 by +894.76%, while revenue for the quarter reached $892.33M , missing expectations by -1.93%.

Dividend declared on 12 May 2023

A dividend of $0.07 per share was announced, adjusted to $0.07. The dividend was paid on 30 May 2023.

Earnings released on 31 Mar 2023

EPS came in at $0.79 surpassing the estimated $0.09 by +794.83%, while revenue for the quarter reached $883.62M , missing expectations by -0.43%.

Earnings released on 31 Dec 2022

EPS came in at $0.77 surpassing the estimated $0.09 by +778.24%, while revenue for the quarter reached $881.79M , beating expectations by +0.02%.

Dividend declared on 15 Nov 2022

A dividend of $0.21 per share was announced, adjusted to $0.21. The dividend was paid on 16 Dec 2022.

Earnings released on 30 Sept 2022

EPS came in at $0.76 surpassing the estimated $0.08 by +841.73%, while revenue for the quarter reached $794.09M , missing expectations by -1.57%.

Earnings released on 30 Jun 2022

EPS came in at $0.85 surpassing the estimated $0.08 by +951.92%, while revenue for the quarter reached $821.27M , beating expectations by +4.55%.

Dividend declared on 5 May 2022

A dividend of $0.07 per share was announced, adjusted to $0.07. The dividend was paid on 23 May 2022.

Earnings released on 31 Mar 2022

EPS came in at $0.68 surpassing the estimated $0.08 by +728.59%, while revenue for the quarter reached $818.28M , beating expectations by +3.26%.

Earnings released on 31 Dec 2021

EPS came in at $0.86 , while revenue for the quarter reached $787.81M .

Dividend declared on 19 Nov 2021

A dividend of $0.21 per share was announced, adjusted to $0.21. The dividend was paid on 17 Dec 2021.

Earnings released on 30 Sept 2021

EPS came in at $0.96 surpassing the estimated $0.09 by +981.45%, while revenue for the quarter reached $795.70M , beating expectations by +2.17%.

Earnings released on 30 Jun 2021

EPS came in at $0.94 , while revenue for the quarter reached $770.75M .

Dividend declared on 7 May 2021

A dividend of $0.08 per share was announced, adjusted to $0.08. The dividend was paid on 24 May 2021.

Earnings released on 31 Mar 2021

EPS came in at $0.84 , while revenue for the quarter reached $750.91M .

Earnings released on 31 Dec 2020

EPS came in at $0.88 , while revenue for the quarter reached $777.98M .

Dividend declared on 10 Nov 2020

A dividend of $0.21 per share was announced, adjusted to $0.21. The dividend was paid on 18 Dec 2020.

Earnings released on 30 Sept 2020

EPS came in at $0.77 , while revenue for the quarter reached $723.37M .

CLPBY Stock Performance

Access detailed CLPBY performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More
Command Palette
Search for a command to run